Actively Recruiting
Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-10-18
300
Participants Needed
2
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Breast cancer has become the world's number one cancer. While its therapeutic efficacy is increasing, how to achieve non-invasive evaluation of the efficacy of neoadjuvant therapy (NAT) for breast cancer patients and thus avoid surgery has become a bottleneck problem that needs to be broken through in clinical diagnosis and treatment. Existing non-invasive evaluation strategies are limited to single-center, single-modality modeling, and have problems such as low performance and poor versatility. Therefore, in the early stage of this study, multi-modality breast cancer patient data from multiple centers across the country were collected and the establishment of an artificial intelligence (AI) efficacy prediction model was preliminarily completed. On this basis, this project intends to further improve the multi-center prospective validation study of the prediction model. The research results will help solve the scientific problem of non-invasive judgment of NAT efficacy in breast cancer patients and provide a new paradigm for the research of high-performance AI diagnosis and treatment auxiliary systems applicable to multiple centers.
CONDITIONS
Official Title
Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated at the research centers between January 1, 2024 and October 31, 2025
- Female patients aged 18 years or older with ECOG score 2 or less
- Pathological biopsy confirmed invasive breast cancer
- AJCC (8th edition) stage I to III breast cancer
- MRI imaging data available before and after neoadjuvant therapy
- Scheduled for mastectomy or breast-conserving surgery after neoadjuvant therapy with postoperative pathology results
You will not qualify if you...
- Bilateral breast cancer, multiple lesions, or occult breast cancer
- Poor quality MRI data
- Prior anti-tumor treatments before enrollment
- Presence of other malignant tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sanhuan Cancer Hospital, Chaoyang District, Beijing(Cancer Hospital, Chinese Academy of Medical Sciences, close medical alliance)
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
2
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
P
peng yuan, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here